In case that corrections are made, an errata will be provided in the following webpage: https://www.rri.kyoto-u.ac.jp/PUB/report/PR/ProgRep2019/ProgRep2019.htmlPR6-1 Effect of a change in reactor power on response of murine solid tumors in vivo, especially on that of quiescent tumor cells, in boron neutron capture therapy /S. Masunaga et al.(31P6-1) [63]PR6-2 Development of new amino acid-type boron carriers for BNCT /A. Matsushita et al.(31P6-2) [64]PR6-3 Molecular mechanism underlying HISP2-mediated radioresistance of hypoxic tumor cells /M. Kobayashi et al.(31P6-3) [65]PR6-4 OH radicals from the indirect actions of neutron beam induce cell killing /R. Hirayama et al.(31P6-4) [66]PR6-5 Intracellular Delivery of Membrane-fluidity Sensitive Boron Liposomes with Tumor-specific Cell Penetrating Peptides /S. Kasaoka et al.(31P6-5) [67]PR6-6 Preparation and Characterization of a Novel Bispecific Antibody That Targets Her2 and BSH for Boron Neutron Capture Therapy /T. Kanai et al.(31P6-6) [68]PR6-7 Development of novel BPA-Tirapazamine hybrid BNCT agent targeting hypoxic tumor cells /Y. Uto et al.(31P6-7) [69]PR6-8 The tumor invasion enhanced by the conditioned-medium after X-irradiation /H. Yasui et al.(31P6-8) [70]PR6-9 Analysis of the response of tumor tissue and cells to BNCT /S. Imamichi et al.(31P6-9) [71]PR6-10 The contribution of blood boron-neutron reaction to subcutaneous tumor growth suppression was equal to that of neutrons irradiation only group /K. Nakai et al.(31P6-10) [72]PR6-11 Cell killing effect of BNCT with novel boron compound SMA glucosamine complex /Y. Matsumoto et al.(31P6-11) [73]PR6-12 Attempts to sensitize tumor cells by exploiting the tumor microenvironment /Y. Sanada et al.(31P6-12) [74
